Chao Zhang

Chao Zhang

Auto-generated profile, based on publicly available information

Chao Zhang

Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China; School of Medicine, South China University of Technology, Guangzhou, People's Republic of China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2017 in OncoImmunology
Verified
Journal Article
Closed access
ZDZhong-Yi Dong
Zhong-Yi Dong
JZJia-Tao Zhang
Jia-Tao Zhang
SLSi-Yang Liu
Si-Yang Liu
JSJian Su
Jian Su
CZChao Zhang
Chao Zhang
YWYI-LONG WU
YI-LONG WU
Patients with EGFR mutations showed unfavorable response to programmed cell death-1 (PD-1) blockade immunotherapy in non-small cell lung cancer (NSCLC). Yet the underlying association between EGFR mutation and immune resistance remains largely unclear. We performed an integrated analysis of PD-ligand 1(PD-L1)/CD8 expression and mutation profile based on the repository database and resected early-stage NSCLC in Guangdong Lung Cancer Institute (GLCI). Meanwhile, 2 pool-analyses were set to clarify the correlation between EGFR mutation and PD-L1 expression, and the association of EGFR status with response to anti-PD-1/L1 therapy. Pool-analysis of 15 public studies suggested that patients with EGFR mutations had decreased PD-L1 expression (odds ratio: 1.79, 95% CI: 1.10–2.93; P = 0.02). Analysis of The Cancer Genome Atlas (TCGA) and the GCLI cohort confirmed the inverse correlation between EGFR mutation and PD-L1 expression. Furthermore, patients with EGFR mutation showed a lack of T-cell infiltration and shrinking proportion of PD-L1+/CD8+ TIL (P = 0.034). Importantly, patients with EGFR mutations, especially the sensitive subtype, showed a significantly decreased mutation burden, based on analysis of the discovery and validation sets. Finally, a pool-analysis of 4 randomized control trials confirmed that patients with EGFR mutation did not benefit from PD-1/L1 inhibitors (Hazard ratio [HR] = 1.09, P = 0.51) while patients with EGFR wild-type did (HR = 0.73, P < 0.00001). This study provided evidence of a correlation between EGFR mutations and an uninflamed tumor microenvironment with immunological tolerance and weak immunogenicity, which caused an inferior response to PD-1 blockade in NSCLCs.

1 November 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
CZChao Zhang
Chao Zhang
JZJianjun Zhang
Jianjun Zhang
FXFang-Ping Xu
Fang-Ping Xu
YWYin-Guang Wang
Yin-Guang Wang
ZXZhi Xie
Zhi Xie
WZWen-Zhao Zhong
Wen-Zhao Zhong

17 April 2019 in The Oncologist
Verified
Journal Article
Open access
PDF file
CZChao Zhang
Chao Zhang
XSXing Sun
Xing Sun
KDKang Dang
Kang Dang
KLKe Li
Ke Li
XGXiao-Wei Guo
Xiao-Wei Guo
WZWen-Zhao Zhong
Wen-Zhao Zhong
Background: Computed tomography (CT) is essential for pulmonary nodule detection in diagnosing lung cancer. As deep learning algorithms have recently been regarded as a promising technique in medical fields, we attempt to integrate a well-trained deep learning algorithm to detect and classify pulmonary nodules derived from clinical CT images.Materials and Methods: Open-source data sets and multicenter data sets have been used in this study. A three-dimensional convolutional neural network (CNN) was designed to detect pulmonary nodules and classify them into malignant or benign diseases based on pathologically and laboratory proven results.Results: The sensitivity and specificity of this well-trained model were found to be 84.4% (95% confidence interval [CI], 80.5%–88.3%) and 83.0% (95% CI, 79.5%–86.5%), respectively. Subgroup analysis of smaller nodules (<10 mm) have demonstrated remarkable sensitivity and specificity, similar to that of larger nodules (10–30 mm). Additional model validation was implemented by comparing manual assessments done by different ranks of doctors with those performed by three-dimensional CNN. The results show that the performance of the CNN model was superior to manual assessment.Conclusion: Under the companion diagnostics, the three-dimensional CNN with a deep learning algorithm may assist radiologists in the future by providing accurate and timely information for diagnosing pulmonary nodules in regular clinical practices.Implications for Practice: The three-dimensional convolutional neural network described in this article demonstrated both high sensitivity and high specificity in classifying pulmonary nodules regardless of diameters as well as superiority compared with manual assessment. Although it still warrants further improvement and validation in larger screening cohorts, its clinical application could definitely facilitate and assist doctors in clinical practice.

25 April 2019 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
CZChao Zhang
Chao Zhang
NLNatasha B. Leighl
Natasha B. Leighl
YWYI-LONG WU
YI-LONG WU
WZWen-Zhao Zhong
Wen-Zhao Zhong
Recent advances in the field of novel anticancer agents prolong patients’ survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing rapid development. Although increasing novel anticancer agents were innovated, how to translate and optimize these novel agents into clinical practice remains to be explored. Besides, toxicities and availability of these drugs in specific regions should also be considered during clinical determination. Herein, we summarize emerging agents including tyrosine kinase inhibitors, checkpoint inhibitors, and other potential immunotherapy such as chimeric antigen receptor T cell for non-small cell lung cancer attempting to provide insights and perspectives of the future in anticancer treatment.

1 April 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
CZChao Zhang
Chao Zhang
SLShao-Lei Li
Shao-Lei Li
QNQiang Nie
Qiang Nie
SDSong Dong
Song Dong
YSYang Shao
Yang Shao
WZWen-Zhao Zhong
Wen-Zhao Zhong

1 January 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
ZDZhong-Yi Dong
Zhong-Yi Dong
CZChao Zhang
Chao Zhang
YLYu-Fa Li
Yu-Fa Li
JSJian Su
Jian Su
ZXZhi Xie
Zhi Xie
YWYI-LONG WU
YI-LONG WU